Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.
The nucleus basalis of Meynert (nbM) was examined using immunocytochemistry for beta-amyloid precursor protein (beta APP) expression in Alzheimer's disease (AD). In mild AD cases, light labeling of the cell body and proximal processes was observed, and small intracellular structures were labeled rarely. In the more severe cases, intense cytoplasmic beta APP labeling was seen, often along with small beta APP-positive structures. Double-labeling experiments demonstrated that in the more severe cases these small structures were also decorated by a neurofibrillary tangle (NFT) antiserum. Other neurons in the severe cases showed incorporation of beta APP into large inclusions, which were also labeled with the NFT antiserum. However, some large inclusions in the severe cases were labeled by the NFT antiserum but contained no beta APP. Extraneuronal NFTs did not show beta APP labeling and did not react with an antibody to the beta-amyloid peptide. These results suggest that increased expression of beta APP coincides with intracellular NFT formation in the nbM, but that the formation of extraneuronal NFTs results in a loss of beta APP immunoreactivity.
Murphy
G M
GM
Department of Psychiatry, Stanford University School of Medicine, California.
Greenberg
B D
BD
Ellis
W G
WG
Forno
L S
LS
Salamat
S M
SM
Gonzalez-DeWhitt
P A
PA
Lowery
D E
DE
Tinklenberg
J R
JR
Eng
L F
LF
D000328:Adult; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D004314:Down Syndrome / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D013377:Substantia Innominata / Q000378:metabolism* / Q000473:pathology
D016564:Amyloid beta-Protein Precursor